StockNews.AI
PRTG
StockNews.AI
55 days

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

1. Portage Biotech confirmed compliance with Nasdaq listing requirements. 2. Company operates in clinical-stage immuno-oncology with novel biologics. 3. Forward-looking statements carry risks like financing uncertainties. 4. Portage was formed under British Virgin Islands laws.

4m saved
Insight
Article

FAQ

Why Bullish?

Compliance with Nasdaq requirements enhances investor confidence, historically correlating with positive price movements.

How important is it?

Successful Nasdaq compliance reassured investors, influencing future investments and stock performance.

Why Short Term?

Immediate investor reactions expected due to compliance news can drive price behavior quickly.

Related Companies

NASDAQ: CRMDNASDAQ: CRTXNASDAQ: ABUS
June 25, 2025 07:00 ET  | Source: Portage Biotech Inc. DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system’s ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looking StatementsAll statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company’s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “plans,” “potential,” “continues,” or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company’s ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2024 and “Business Environment – Risk Factors” in the Company’s Management’s Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company’s Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law. For More Information:Portage BiotechAlexander Pickett, Chief Executive Officerir@portagebiotech.com

Related News